-
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
Thursday, March 23, 2017 - 10:53am | 415Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s refinancing announcement on Tuesday shouldn't be celebrated by investors, at least according to Gadfly's Max Nisen. Nisen noted Valeant's "financial wizardry" doesn't address Valeant's long-term $30 billion debt load although it may ease short-term...
-
Is Teva's 4% Dividend Yield Safe?
Tuesday, February 7, 2017 - 2:42pm | 329Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) plunged more than 5 percent after the company's CEO and President Erez Vigodman will step down, effective immediately. Yithak Peterburg, Teva's chairman since early 2015, will replace Vigodman at a time when the company is also...
-
Biopharmaceutical Investors Among The Most Fed Up With The Election
Tuesday, November 8, 2016 - 1:53pm | 322Read More...Voting for the U.S. presidential election is underway and one group of investors couldn't be more relieved that the end is in sight. As noted by Gadfly's Max Nisen, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has fallen 23 percent year-to-date while the Bloomberg...
-
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
Thursday, September 22, 2016 - 2:43pm | 459Read More...Analysts at Gabelli hypothesized on Wednesday that Allergan plc Ordinary Shares (NYSE: AGN) is "playing chess," strategically buying smaller companies with the ultimate end goal of acquiring Gilead Sciences, Inc. (NASDAQ: GILD). Not so fast, says Bloomberg Gadfly's Max Nisen. The "mother of all...
